Patient : About Novoste

Of the 900,000 people who undergo angioplasty every year in the U.S., more than 700,000 receive stents, little metal devices that help hold their arteries open. Unfortunately for 15% to 20% of those who receive stents, new tissue growth sometimes clogs the stents, resulting in the need to re-open them.

"I've lost count of the angioplasties I've had in the last decade. After my radiation procedure, however, I feel better than I have in years. What Novoste is trying to do in medicine I've been trying to do in the ministry - heal hearts so that people can have a better quality of life."
Rev. Harold Murphree, Retired Minister
Dacula, Georgia

Novoste Corporation, based in Atlanta, Georgia, develops advanced medical treatments for coronary and vascular diseases and is the worldwide leader in vascular brachytherapy - radiation therapy delivered inside a blood vessel to prevent it from re-closing (restenosis) following balloon angioplasty and other catheter-based interventional procedures. The NovosteT Beta-CathT System is commercially available in the United States, as well as in the European Union and several other countries. The Beta-CathT System is primarily used to treat patients suffering from in-stent restenosis, a condition in which coronary stents become blocked with new tissue growth. It is estimated that approximately 150,000 patients in the U.S. need treatment for this condition annually. Novoste has also initiated clinical trials to investigate the role of vascular brachytherapy to treat peripheral arterial disease and arterial-venous dialysis graft stenosis.